Clinical trials: Children With Cancer
Brain and Central Nervous System Tumors
Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma
RATIONALE: Drugs used in chemotherapy, such as cisplatin and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00360945
- Testing
- cisplatin, temozolomide, fluorescence in situ hybridization
- Where
- 23 sites in France, Ireland and 1 more
- Volunteers
- 87 people
- Sponsor
- Children's Cancer and Leukaemia Group
Neuroblastoma
Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy may kill more tumor cells.
- Trial name
- NCT00410631
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- 80 sites in Germany, Switzerland
- Volunteers
- 642 people
- Sponsor
- German Society for Pediatric Oncology and Hematology GPOH gGmbH
Low-grade Glioma, Recurrent Low Grade Glioma
Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma
This study aims to evaluate the efficacy of Laser Interstitial Thermal Therapy (LITT) in treating recurrent or progressive, low-grade gliomas (LGG) in pediatric, adolescent and young adult patients.
- Conditions
- Low-grade Glioma, Recurrent Low Grade Glioma, Low Grade Glioma of Brain, Pediatric Cancer
- Trial name
- NCT07506239
- Testing
- Laser Interstitial Thermal Therapy (LITT), Magnetic resonance imaging (MRI), Questionnaires
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Francisco
Leukemia
Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells.
- Trial name
- NCT00002812
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 2,078 people
- Sponsor
- Children's Oncology Group
Neuroblastoma
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
- Trial name
- NCT04106219
- Testing
- LY3295668 Erbumine, Topotecan, Cyclophosphamide
- Where
- 17 sites in United States, Australia and 7 more
- Volunteers
- 71 people
- Sponsor
- Eli Lilly and Company
Non-Hodgkin Lymphoma, Burkitt Lymphoma
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this…
- Conditions
- Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma
- Trial name
- O-ICE (NCT02393157)
- Testing
- Obinutuzumab, Liposomal ARA-C, Ifosfamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New York Medical College
Leukemia
Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder
RATIONALE: Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of abnormal cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00411281
- Testing
- cytarabine, observation
- Sponsor
- Children's Oncology Group
Olfactory Neuroblastoma, Esthesioneuroblastoma
A Natural History Study of Children and Adults With Olfactory Neuroblastoma
Background: Olfactory neuroblastoma (ONB) is a rare cancer. It grows from tissue in the upper part of the nose cavity, related to the sense of smell and can affect a person s sense of smell.
- Trial name
- NCT04755205
- Where
- United States
- Volunteers
- 525 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma, Ewings Sarcoma
Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma
This treatment study for relapsed high-risk neuroblastoma, Ewings sarcoma, osteogenic sarcoma, rhabdomyosarcoma or synovial sarcoma involves an autologous cancer testis (CT) antigen specific dendritic cell (DC) vaccine preceded…
- Conditions
- Neuroblastoma, Ewings Sarcoma, Osteogenic Sarcoma, Rhabdomyosarcoma
- Trial name
- NCT01241162
- Testing
- Autologous dendritic cell vaccine with adjuvant
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Louisville
Relapsed or Refractory Neuroblastoma
Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children
This single-arm, multicenter clinical study will treat the patient who have relapsed or refractory neuroblastoma with an infusion of the patient's own T cells that have been genetically modified to express a chimeric antigen…
- Trial name
- NCT02919046
- Testing
- GD2-targeted CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 22 people
- Sponsor
- Sinobioway Cell Therapy Co., Ltd.
Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
This phase II trial is studying how well oxaliplatin works in treating young patients with recurrent solid tumors that have not responded to previous treatment.
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Hepatoblastoma, Childhood Hepatocellular Carcinoma
- Trial name
- NCT00091182
- Testing
- oxaliplatin
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- National Cancer Institute (NCI)
Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Promyelocytic Leukemia (M3)
Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. This phase I trial is studying the side effects and best dose of decitabine in treating children with relapsed or…
- Conditions
- Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Promyelocytic Leukemia (M3), Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia
- Trial name
- NCT00042796
- Testing
- decitabine, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Medulloblastoma, Glioblastoma Multiforme
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Patients will receive a vaccine called SurVaxM on this study. While vaccines are usually thought of as ways to prevent diseases, vaccines can also be used to treat cancer.
- Conditions
- Medulloblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High-grade Astrocytoma NOS
- Trial name
- NCT04978727
- Testing
- SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years, SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years, SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years
- Where
- 14 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia, Pediatric Acute Myeloid Leukemia
Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML
This is a prospective, single-arm, open-label clinical study to evaluate the efficacy and safety of Selinexor combined with a standardized induction chemotherapy regimen (ZJCH-AML) for children with NUP98-fusion positive Acute…
- Conditions
- Acute Myeloid Leukemia, Pediatric Acute Myeloid Leukemia, NUP98 Fusion-positive Acute Myeloid Leukemia
- Trial name
- NCT07437170
- Testing
- Selinexor, ZJCH-AML Standardized Chemotherapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Brain and Central Nervous System Tumors
Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00392886
- Testing
- carboplatin, cisplatin, cyclophosphamide
- Where
- 37 sites in United States, Australia and 3 more
- Volunteers
- 120 people
- Sponsor
- Children's Hospital Los Angeles
Recurrent Childhood Medulloblastoma, Recurrent Ependymoma
Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors
This phase I trial studies the side effects and best dose of expanded natural killer cells in treating younger patients with brain tumors that have come back or do not respond to treatment.
- Conditions
- Recurrent Childhood Medulloblastoma, Recurrent Ependymoma, Recurrent Medulloblastoma
- Trial name
- NCT02271711
- Testing
- Laboratory Biomarker Analysis, Natural Killer Cell Therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
RATIONALE: INCB18424 (Ruxolitinib) may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase 1 clinical trial is studying the side effects and best dose of INCB18424 in…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT01164163
- Testing
- ruxolitinib phosphate, laboratory biomarker analysis, pharmacological study
- Where
- 24 sites in United States
- Volunteers
- 49 people
- Sponsor
- Children's Oncology Group
Pediatric Cancer
Physical Activity in Pediatric Cancer (PAPEC)
The aim of this randomized controlled trial on Physical Activity and Pediatric Cancer (PAPEC) is to assess the impact of an exercise program intervention in pediatric cancer patients undergoing chemotherapy for solid tumors.
- Trial name
- PAPEC (NCT01645436)
- Testing
- exercise training
- Where
- Spain
- Volunteers
- 49 people
- Sponsor
- Universidad Europea de Madrid
Rhabdomyosarcoma
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
Background: Rhabdomyosarcoma (RMS) is a cancer of soft tissues. It is the most common soft tissue sarcoma seen in children. RMS cancer cells have a protein called FGFR4 on their surface.
- Trial name
- NCT06865664
- Testing
- fludarabine, cyclophosphamide, cetuximab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Childhood, Brain Tumor, Pediatric
Social Emotional Development in Young Children With Cancer
Many children with cancer are diagnosed in early childhood, and as such, will likely miss key social experiences such as participation in preschool or kindergarten, playing on playgrounds, and other normative experiences.
- Trial name
- NCT03086421
- Testing
- Questionnaires
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- St. Jude Children's Research Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.